10/15/2026

Janusmed sex and gender

Janusmed sex and gender – azelastine

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Azelastine

Azelastine

Class : A

Show all info

Print

Contact us

  1. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - Dymista (azelastine / fluticasone). Drugs@FDA [www]. [updated 2012-05-01, cited 2026-04-23].

  2. Stjarne P, Nguyen DT, and Kuhl HC. Real-Life Effectiveness of MP-AzeFlu (Dymista) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale. Pragmat Obs Res. 2023;14:1-11.

  3. Food and Drug Administration (FDA). Statistical review - Dymista (azelastine / fluticasone). Drugs@FDA [www]. [updated 2012-05-01, cited 2026-04-23].

  4. Food and Drug Administration (FDA). Medical review - Dymista (azelastine / fluticasone). Drugs@FDA [www]. [updated 2012-05-01, cited 2026-04-23].

  5. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]

  1. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - Dymista (azelastine / fluticasone). Drugs@FDA [www]. [updated 2012-05-01, cited 2026-04-23].
  2. Stjarne P, Nguyen DT, and Kuhl HC. Real-Life Effectiveness of MP-AzeFlu (Dymista) in Swedish Patients with Persistent Allergic Rhinitis, Assessed by the Visual Analogue Scale. Pragmat Obs Res. 2023;14:1-11.
  3. Food and Drug Administration (FDA). Statistical review - Dymista (azelastine / fluticasone). Drugs@FDA [www]. [updated 2012-05-01, cited 2026-04-23].
  4. Food and Drug Administration (FDA). Medical review - Dymista (azelastine / fluticasone). Drugs@FDA [www]. [updated 2012-05-01, cited 2026-04-23].
  5. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]